Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin (ISOTOVE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02667925 |
|
Recruitment Status :
Withdrawn
(Because of the obsolescence of the study)
First Posted : January 29, 2016
Last Update Posted : October 11, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The treatment of advanced ovarian cancer is based on the combination of chemotherapy based on platinum salt and surgery whose quality is the major prognostic factor.
A meta-analysis of retrospective series had shown that for every 10% increase in the complete cytoreduction rates were increased by 5.5% overall survival time (Markman et al, 2001). Currently, it is recognized that the best chance of survival conferred to patients whose initial surgical residue is zero (Harter et al, 2009).
However, even if macroscopically complete surgery and whatever the type of systemic chemotherapy, peritoneal recurrence remains high for more than 75%.
To reducing it of recurrence, a therapeutic approach is to administer chemotherapy intraperitoneally.
The intraperitoneal chemotherapy consists to administer the drug directly into the peritoneal cavity.
Alberts et al, 1996 and Armstrong et al, 2006 compared the efficacy in terms of survival of an intraperitoneal chemotherapy according to this method with a conventional systemic chemotherapy. Alberts reported a significant improvement in the median overall survival. Armstrong shows in addition a decreased risk of recurrence.
It must be remembered that:
- The establishment of an intra-abdominal catheter does not always ensure complete flow of drugs into the peritoneal cavity (major postoperative adhesions).
- There may be problems of catheters becoming blocked and requiring local treatment; these problems can cause abdominal pain whose care is difficult. Thus almost half of patients fail to get all six courses of intraperitoneal chemotherapy.
Thus, the investigators propose to estimate the flow of intraperitoneal chemotherapy with IP peritoneal scintigraphy, using a radiotracer (nanocis®). The investigators hypothesize that the movement of colloids in peritoneal cavity is similar to the circulation of chemotherapy within the peritoneal cavity (From Forni et al, 1993, Varia et al, 2003, Young et al, 2003, Dawson et al, 2011). The accumulation of radiotracer will be more correlated with abdominal pain sites described by the patient as well as peritoneal recurrence sites found during monitoring.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Cancer | Drug: Intraperitoneal cisplatin with nanocis | Not Applicable |
Epithelial ovarian cancer is the fifth leading cause of female cancer and the leading cause of death among gynecological cancers (Alberts et al, 2002). The treatment of advanced ovarian cancer is based on the combination of chemotherapy based on platinum salt and surgery whose quality is the major prognostic factor.
A meta-analysis of retrospective series had shown that for every 10% increase in the complete cytoreduction rates were increased by 5.5% overall survival time (Markman et al, 2001). Currently, it is recognized that the best chance of survival conferred to patients whose initial surgical residue is zero (Harter et al, 2009).
However, even if macroscopically complete surgery and whatever the type of systemic chemotherapy, peritoneal recurrence remains high for more than 75%.
To reducing it of recurrence, a therapeutic approach is to administer chemotherapy intraperitoneally.
The intraperitoneal chemotherapy consists to administer the drug directly into the peritoneal cavity at a frequency that is related to systemic chemotherapy (every 3 weeks).
Alberts et al, 1996 and Armstrong et al, 2006 compared the efficacy in terms of survival of an intraperitoneal chemotherapy according to this method with a conventional systemic chemotherapy. Alberts reported a significant improvement in the median overall survival (49 vs 41 months). Armstrong shows in addition a decreased risk of recurrence.
It must be remembered that:
- The establishment of an intra-abdominal catheter does not always ensure complete flow of drugs into the peritoneal cavity (major postoperative adhesions).
- There may be problems of catheters becoming blocked and requiring local treatment; these problems can cause abdominal pain whose care is difficult. Thus almost half of patients fail to get all six courses of intraperitoneal chemotherapy.
Thus, the investigators propose to estimate the flow of intraperitoneal chemotherapy with IP peritoneal scintigraphy, using a radiotracer (nanocis®). The investigators hypothesize that the movement of colloids in peritoneal cavity is similar to the circulation of chemotherapy within the peritoneal cavity (From Forni et al, 1993, Varia et al, 2003, Young et al, 2003, Dawson et al, 2011). The accumulation of radiotracer will be more correlated with abdominal pain sites described by the patient as well as peritoneal recurrence sites found during monitoring.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 0 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Study of the Isotopic Distribution of Intraperitoneal Postoperative Locoregional Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin |
| Study Start Date : | March 2016 |
| Actual Primary Completion Date : | September 2016 |
| Actual Study Completion Date : | September 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Intervention arm
Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
|
Drug: Intraperitoneal cisplatin with nanocis
Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy |
- Quantification by visual analysis the intensity of fixation of the solvent characterized in the intraperitoneal cavity [ Time Frame: During the 6 cycles of chemotherapy, that is during 18 weeks ]
The intensity of fixation will be defined as followed:
0: no fixation
- fixation of low intensity
- fixation of high intensity
- Note adverse events assessed with CTCAE v4.0 [ Time Frame: During the 6 cycles of chemotherapy, that is during 18 weeks ]The treatment-related adverse events will be assessed with CTCAE v4.0
- Correlate pain intensity to fixation intensity in the peritoneal cavity [ Time Frame: During the 6 cycles of chemotherapy, that is during 18 weeks ]Pain intensity will be measured with EVA scale
- dosimetric study with peritoneal scintigraphy [ Time Frame: During the 6 cycles of chemotherapy, that is during 18 weeks ]This study will be realised only for the first three patients included in the trial
- Correlate site of relapse to localisation of labeled intraperitoneal solvent by nanocis in peritoneal cavity [ Time Frame: During 5 years after chemotherapy ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Performance Status 0-2
- PNN> 1.5.109 / L (without added GCSF)
- Plaquettes> 100. 109 / L
- Bilirubine inferior or equal to 1.5 times the upper normal value (VNS)
- ASAT And ALT inferior or equal to 2.5 upper normal value (VNS)
- Alkaline Phosphatase inferior or equal to2.5 upper normal value (VNS)
- Clairance Creatinine> 60ml / min Normal -Ionogramme
- PTT <1.5 times the upper normal value (VNS) (heparin, or other accepted lovenox anticoagulants)
- PT / INR inferior or equal to 1.5 upper normal value (VNS) (or INR between 2 and 3, if the patient receives a stabilized dose of Warfarin)
- Patient operated first line without macroscopic residual for ovarian cancer or primary peritoneal or tubal stage IIIC or IV peritoneal pleural
- Minimum Required for surgery: hysterectomy, oophorectomy, pelvic lymphadenectomy and para-aortic omentectomy
- Patient requiring adjuvant chemotherapy
- Compulsory affiliation to a social security scheme.
- Obtaining informed consent in writing, signed and dated.
Exclusion Criteria:
- Patient with cognitive and psychiatric disorders.
- Patient deprived of liberty by a court or administrative.
- Patient having directions against the achievement of chemotherapy
- Concomitant treatment with a drug test, participation in another therapeutic clinical trial within 30 days
- Pregnant women
- Nursing women
- Patient with recognized hypersensitivity to cisplatin or platinum-containing products
- Patient with hypersensitivity recognized paclitaxel or any of the excipients
- Patient must be vaccinated against yellow fever
- Patient before taking phenytoin for prophylactic purposes
- Patient with hearing impairment
- Patient with hepatic impairment
- Patient with renal impairment Sensory or motor -Neuropathies> grade 1 (CTCAE)
- Hépatite Or severe infection requiring parenteral antibiotics
- Serious non-healing wound or ulcer, or bone fracture
- Fistule Abdominal or gastrointestinal perforation, or intra-abdominal abscess in the 28 days preceding the intraperitoneal chemotherapy Clinical -Symptômes, gastrointestinal obstruction or signs and / or which require a hydration and / or parenteral nutrition
- Patientes Has had or currently with inflammatory bowel disease
- Active bleeding or medical condition that carries a high risk of bleeding (eg, known coagulation disorders, coagulopathy, or tumor with large vessels)
- Cerebrovascular accident (CVA) or transient ischemic attack, or subarachnoid hemorrhage in the last 6 months
-
Disease clinically significant cardiovascular, including:
- uncontrolled hypertension, defined as systolic blood pressure> 150mmHg or diastolic> 90mmHg
- myocardial infarction or unstable angina within the last 6 months
- NYHA class II-IV congestive heart failure
- serious cardiac arrhythmia requiring treatment: -an asymptomatic atrial fibrillation with controlled ventricular rate supraventricular tachycardia or controlled with medication and is authorized asymptomatic peripheral vascular disease o ≥ Grade 2 (CTCAE) (brief [less than 24 hours] ischemia episodes managed non-surgically and without permanent deficit)
- Antecedents of Hemorrhage or stroke (stroke), transient ischemic attack, or subarachnoid in the last 6 months Major Surgery within 28 days prior to inclusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02667925
| France | |
| Centre Jean Perrin | |
| Clermont-Ferrand, France, 63000 | |
| Principal Investigator: | Christophe Pomel, MD, PhD | Centre Jean Perrin |
| Responsible Party: | Centre Jean Perrin |
| ClinicalTrials.gov Identifier: | NCT02667925 |
| Other Study ID Numbers: |
2012-004103-12 |
| First Posted: | January 29, 2016 Key Record Dates |
| Last Update Posted: | October 11, 2016 |
| Last Verified: | September 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
ovarian cancer intraperitoneal chemotherapy |
|
Ovarian Neoplasms Carcinoma Peritoneal Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms |
Endocrine System Diseases Gonadal Disorders Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Abdominal Neoplasms Digestive System Neoplasms Digestive System Diseases Peritoneal Diseases Cisplatin Antineoplastic Agents |